MPC-150-IM (rexlemestrocel-L; Mesoblast) consists of highly purified, immunoselected mesenchymal precursor cells (MPCs). These cells release a range of molecules that stimulate both blood vessel growth and regeneration of heart muscle, while also reducing scar formation and harmful inflammatory responses within the damaged tissues. These rare cells are isolated from tissues around the donor’s blood vessels and then expanded in large numbers before being administered to patients.
LIST OF FIGURES
7 Figure 21: Datamonitor Healthcare’s drug assessment summary of Farxiga for chronic heart failure
9 Figure 22: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: MPC-150-IM drug profile
6 Table 2: MPC-150-IM’s late-phase trials in chronic heart failure
12 Table 3: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.